Eric Xueyu Chen

547 total citations
54 papers, 370 citations indexed

About

Eric Xueyu Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Eric Xueyu Chen has authored 54 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Eric Xueyu Chen's work include Colorectal Cancer Treatments and Studies (25 papers), Cancer Genomics and Diagnostics (13 papers) and Lung Cancer Treatments and Mutations (13 papers). Eric Xueyu Chen is often cited by papers focused on Colorectal Cancer Treatments and Studies (25 papers), Cancer Genomics and Diagnostics (13 papers) and Lung Cancer Treatments and Mutations (13 papers). Eric Xueyu Chen collaborates with scholars based in Canada, United States and Spain. Eric Xueyu Chen's co-authors include Lillian L. Siu, Philippe L. Bédard, Wenjiang Zhang, Amit M. Oza, Blaise Clarke, Gelareh Zadeh, Lisa Wang, Ben Tran, Jennifer J. Knox and Michael Reedijk and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Oncologist.

In The Last Decade

Eric Xueyu Chen

47 papers receiving 368 citations

Peers

Countries citing papers authored by Eric Xueyu Chen

Since Specialization

Citations

This map shows the geographic impact of Eric Xueyu Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Xueyu Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Xueyu Chen more than expected).

Fields of papers citing papers by Eric Xueyu Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Xueyu Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Xueyu Chen. The network helps show where Eric Xueyu Chen may publish in the future.

Co-authorship network of co-authors of Eric Xueyu Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Xueyu Chen. A scholar is included among the top collaborators of Eric Xueyu Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Xueyu Chen. Eric Xueyu Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Amivantamab plus FOLFOX or FOLFIRI in RAS/BRAF wild-type metastatic colorectal cancer: Long-term follow-up from the phase 1b/2 OrigAMI-1 study. 2026 ·Journal of Clinical Oncology ·Eric Xueyu Chen, Rozita Abdul Malik, Yu‐Li Su, Pei Jye Voon, (unknown), Dirk Arnold, J. Randolph Hecht, (unknown), (unknown), (unknown), Sreenivasa R Chandana, (unknown), Sanjib Chowdhury, (unknown), (unknown), Mahesh Daksh, (unknown), Seema Sethi, (unknown)	0
2	Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced HCC: A phase II study (PEMRAD). 2025 ·Journal of Clinical Oncology ·Grainne M. O’Kane, Aruz Mesci, Eric Xueyu Chen, (unknown), Raymond Jang, Ben X. Wang, Rebecca M. Prince, Giselle M. Boukhaled, Aisling Barry, Mark Doherty, David Wong, Lisa Wang, Anna Dodd, Laura A. Dawson, Jennifer J. Knox	0
3	Amivantamab with or without chemotherapy in right-sided metastatic colorectal cancer: Updated results from OrigAMI-1, an open-label, phase 1b/2 study. 2025 ·Journal of Clinical Oncology ·Kanwal Raghav, Eric Van Cutsem, Dirk Arnold, Paul E. Oberstein, (unknown), Marcia Cruz‐Correa, Eric Xueyu Chen, Sae‐Won Han, Rozita Abdul Malik, Cathy Eng, Vı́ctor Moreno, Sanjib Chowdhury, Ryota Iwasawa, Robert W. Schnepp, (unknown), Patricia Lorenzini, Mahadi Baig, Filippo Pietrantonio, J. Randolph Hecht	1
4	Clonal hematopoiesis of indeterminate potential (CHIP), treatment outcomes and adverse events in gastrointestinal cancers: A pooled analysis of clinical trial and real-world data. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Emma Titmuss, James T. Topham, David F. Schaeffer, Aly Karsan, Howard J. Lim, Cheryl Ho, Sharlene Gill, Hagen F. Kennecke, Derek J. Jonker, Eric Xueyu Chen, Daniel J. Renouf, Christopher J. O’Callaghan, Jonathan M. Loree	0
5	Integrating Patient-Reported Outcomes Into Prognostication in Gastroesophageal Cancer: Results of a Population-Based Retrospective Cohort Analysis 2024 ·The Oncologist ·(unknown), (unknown), Zeynep Baskurt, (unknown), Xin Wang, Carly C. Barron, Raymond Woo-Jun Jang, Eric Xueyu Chen, Carol J. Swallow, Aruz Mesci, Jonathan Yeung, Rebecca Wong, Savtaj S. Brar, Patrick Veit‐Haibach, John Kim, (unknown), Hiroko Aoyama, Elena Elimova	0
6	A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations. 2024 ·Journal of Clinical Oncology ·Daneng Li, Eric Xueyu Chen, (unknown), David Hsieh, Jimmy J. Hwang, Lynn G. Feun, Joseph W. Franses, Gentry Teng King, Thomas M Drake, Toshiyasu Suzuki, Thomas G. Bird, Stephen Horrigan, Jean Chang, David D. Stenehjem, Casey Cunningham	3
7	Impact of concurrent antibiotics on survival with immunotherapy in metastatic colorectal and pancreatic cancer. 2024 ·Journal of Clinical Oncology ·Cynthia Yeung, Emma Titmuss, Dongsheng Tu, Daniel J. Renouf, Sharlene Gill, Jennifer J. Knox, Eric Xueyu Chen, Christopher J. O’Callaghan, Jonathan M. Loree	1
8	Reversion of RAS mutations in metastatic colorectal cancer in the CCTG CO.26 clinical trial. 2023 ·Journal of Clinical Oncology ·Florence T.H. Wu, James T. Topham, Christopher J. O’Callaghan, Harriet Feilotter, Hagen F. Kennecke, Kimberly C. Banks, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Eric Xueyu Chen, Jonathan M. Loree	1
9	Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26. 2022 ·Journal of Clinical Oncology ·Eric Xueyu Chen, Jonathan M. Loree, Dongsheng Tu, Christopher J. O’Callaghan, Hagen F. Kennecke, Derek J. Jonker, (unknown), Bruce Colwell, Mohammed Harb, Nathalie Aucoin, Félix Couture, Setareh Samimi, Petr Kavan, F. Aubin, (unknown), John R. Goffin, Scott Berry, Tahir Abbas, Sheryl Koski, Alice C. Wei	1
10	Comparison of four clinical prognostic scores in patients with advanced gastric and esophageal cancer. 2022 ·Journal of Clinical Oncology ·(unknown), Osvaldo Espin‐Garcia, (unknown), Hiroko Aoyama, Michael J. Allen, Xin Wang, Gail Darling, Jonathan Yeung, Carol J. Swallow, Savtaj S. Brar, Patrick Veit‐Haibach, Sangeetha Kalimuthu, Rebecca Wong, Eric Xueyu Chen, Grainne M. O’Kane, Raymond Woo-Jun Jang, Elena Elimova	1
11	Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC). 2021 ·Journal of Clinical Oncology ·Jonathan M. Loree, James T. Topham, Hagen F. Kennecke, Harriet Feilotter, (unknown), Young S. Lee, Weimin Li, Katie Quinn, Kimberly C. Banks, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Christopher J. O’Callaghan, Eric Xueyu Chen	4
12	Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts) with metastatic esophageal cancer. 2020 ·Journal of Clinical Oncology ·(unknown), Katrina Hueniken, (unknown), (unknown), (unknown), (unknown), Kirsty Taylor, M. Catherine Brown, Eric Xueyu Chen, Jennifer J. Knox, Raymond Woo-Jun Jang, Rebecca Wong, Gail Darling, Wei Xu, Elena Elimova, Geoffrey Liu, Dmitry Rozenberg, Micheal McInnis, Aline Fusco Fares	1
13	Phase II basket trial of olaparib and durvalumab in patients (pts) with isocitrate dehydrogenase (IDH) mutated solid tumors. 2020 ·Journal of Clinical Oncology ·Eric Xueyu Chen, Grainne M. O’Kane, Warren Mason, Jennifer J. Knox, Albiruni Ryan Abdul Razak, Gelareh Zadeh	3
14	Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma. 2019 ·Journal of Clinical Oncology ·Kirsty Taylor, Osvaldo Espin‐Garcia, Di Jiang, Daniel Yokom, (unknown), (unknown), Bryan Chan, (unknown), Hao‐Wen Sim, Akina Natori, Geoffrey Liu, Gail Darling, Rebecca Wong, Eric Xueyu Chen, Raymond Woo-Jun Jang, Patrick Veit‐Haibach, Dmitry Rozenberg, Elena Elimova	5
15	Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC). 2018 ·Journal of Clinical Oncology ·Di Jiang, (unknown), (unknown), (unknown), Hao‐Wen Sim, Akina Natori, Bryan Chan, Daniel Yokom, (unknown), Eric Xueyu Chen, Geoffrey Liu, Jennifer J. Knox, Carol J. Swallow, Gail Darling, Savtaj S. Brar, Sara Hafezi‐Bakhtiari, James Conner, Raymond Woo-Jun Jang, Elena Elimova	1
16	Relationship between human epidermal growth factor receptor 2 (HER2) status and central nervous system metastases in gastroesophageal cancer. 2018 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Di Jiang, Hao‐Wen Sim, Akina Natori, Bryan Chan, Daniel Yokom, (unknown), Lisa W. Le, Eric Xueyu Chen, Geoffrey Liu, Carol J. Swallow, Gail Darling, Paul Kongkham, David Shultz, Sara Hafezi‐Bakhtiari, James Conner, Elena Elimova, Raymond Woo-Jun Jang	1
17	Association of isocitrate dehydorgenase-1 (IDH-1) mutations with elevated oncometabolite 2-hydroxyglutarate (2HG) in advanced colorectal cancer. 2016 ·Journal of Clinical Oncology ·Nazanin Fallah‐Rad, Philippe L. Bédard, Lillian L. Siu, Suzanne Kamel‐Reid, Helen Chow, Weijiang Zhang, Raymond Jang, Monika K. Krzyzanowska, Albiruni R. Abdul Razak, Eric Xueyu Chen	7
18	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) 2013 ·Investigational New Drugs ·Suzanne Richter, Philippe L. Bédard, Eric Xueyu Chen, Blaise Clarke, Ben Tran, Sébastien J. Hotte, Anastasios Stathis, Hal W. Hirte, Albiruni R. Abdul Razak, Michael Reedijk, Zhuo Chen, Brenda Cohen, Wenjiang Zhang, Lisa Wang, S. Percy Ivy, Malcolm J. Moore, Amit M. Oza, Lillian L. Siu, Elaine McWhirter	68
19	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). 2013 ·Journal of Clinical Oncology ·Philippe L. Bédard, Amit M. Oza, Ming‐Sound Tsao, Natasha B. Leighl, Frances A. Shepherd, Eric Xueyu Chen, Ian F. Tannock, Monika K. Krzyzanowska, Neesha C. Dhani, Blaise Clarke, Hal K. Berman, Stefano Serra, Kenneth J. Craddock, Dianne Chadwick, Tong Zhang, Mahadeo A. Sukhai, Celeste Yu, Aaron R. Hansen, Suzanne Kamel‐Reid, Lillian L. Siu	20
20	A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. 2012 ·Journal of Clinical Oncology ·Scott A. Laurie, Benjamin Solomon, Lesley Seymour, Peter Ellis, Glenwood Goss, Frances A. Shepherd, Michael Boyer, Andrew Arnold, Philip Clingan, Francis Laberge, (unknown), Vera Hirsh, Mauro Zukin, Martin R. Stockler, Christopher W. Lee, Eric Xueyu Chen, (unknown), Keyue Ding, Penelope Ann Bradbury	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact